A drug targeting 5‑lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F‑positive polycythemia vera in vitro
Authors:
Open Access
- 4 March 2021
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 21 (5) , 1-10
Abstract
Janus kinase 2 (JAK2) inhibitors, the first targeted treatments for myeloproliferative neoplasms (MPNs), provide substantial benefits, including a marked reduction in splenomegaly and MPN‑associated symptoms. However, these drugs rarely induce molecular remission in patients with MPNs. Zileuton, a 5‑lipoxygenase (5‑LO) inhibitor, has been demonstrated to selectively deplete hematopoietic stem cells (HSCs) expressing a JAK2 point mutation (JAK2V617F) in mouse models of JAK2V617F‑induced polycythemia vera (PV). To determine the potential activity of 5‑LO inhibitors in combination with JAK inhibitors against human PV HSCs, the present study first analyzed 5‑LO expression in CD34+ bone marrow cells from patients with JAK2V617F‑positive PV using western blotting and reverse transcription‑quantitative PCR, and then examined the effect of zileuton combined with ruxolitinib on colony formation using a colony formation assay. Furthermore, cell cycle and apoptosis in CD34+ cells from patients with PV and healthy volunteers were determined by flow cytometry. In the present study, 5‑LO expression was upregulated in CD34+ cells from patients with PV compared with in CD34+ cells from healthy volunteers. Higher levels of leukotriene B4, a product of the 5‑LO signaling pathway, were detected in patients with PV compared with in healthy volunteers. Zileuton treatment suppressed the colony formation of CD34+ cells from patients with PV in a dose‑dependent manner. Furthermore, zileuton and ruxolitinib exerted their anticancer effects by suppressing hematopoietic colony formation, inducing apoptosis and arresting the cell cycle of human CD34+ cells from patients with PV. The combination of these two drugs exerted a more beneficial effect than either agent alone. Based on these data, zileuton enhanced the antitumor activity of low‑dose ruxolitinib in hematopoietic progenitor cells from patients with PV, providing conceptual validation for further clinical applications of combination treatment with ruxolitinib and zileuton for patients with PV.Keywords
This publication has 51 references indexed in Scilit:
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesJournal of Hematology & Oncology, 2017
- Molecular insights into regulation of JAK2 in myeloproliferative neoplasmsBlood, 2015
- Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltrationOncogene, 2014
- 5-Lipoxygenase Antagonist therapy: a new approach towards targeted cancer chemotherapyActa Biochimica et Biophysica Sinica, 2013
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- Philadelphia Chromosome–Negative Myeloproliferative Disorders: Biology and TreatmentTransplantation and Cellular Therapy, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001